Alibaba Shares Rise on AI Chip Launch and Expansion Plans

Alibaba Group Holding Limited (BABA) experienced a notable increase in its share price on the morning of the report, driven by two significant announcements. Firstly, the e-commerce and technology giant unveiled what it claims to be China's most powerful artificial intelligence (AI) chip. This development positions Alibaba to compete more effectively in the rapidly advancing AI hardware sector, a critical component for powering advanced AI models and data-intensive applications. The company did not provide specific details on the chip's architecture or performance benchmarks in the initial announcement, but its designation as "China's most powerful" suggests a significant leap in domestic AI chip capabilities.

Secondly, Alibaba announced ambitious plans to expand its data center capacity in the coming years. Data centers are the foundational infrastructure for cloud computing, AI services, and large-scale data processing. This expansion signals Alibaba's commitment to scaling its cloud services and AI offerings, catering to growing demand both domestically and internationally. The increased capacity is expected to support the deployment of its new AI chips and enhance its overall cloud computing infrastructure, a key growth area for the company.

In separate news, ON Holdings (ONON), a company involved in athletic footwear and apparel, also saw its stock receive a boost. The company anticipates sales growth in the high teens over the next few years. This positive outlook is attributed, in part, to ON Holdings' strategic move into new sports markets, specifically mentioning golf and football. This diversification into team sports and a more niche sport like golf indicates a strategy to broaden its customer base and revenue streams beyond its current core athletic offerings.

Additionally, Viking Therapeutics (VKTX) shares experienced a substantial surge. This significant movement followed the release of data from its VK2735-102 maintenance study. The study focused on VK2735, an experimental drug designed for obesity treatment. The data indicated that subjects treated with VK2735 maintained up to 97% of their weight loss when switched to a dosing schedule of every-other-week. This contrasts sharply with the 61% weight loss maintenance observed in the placebo group. Analysts at Leerink described the data as "stellar," suggesting that these results significantly strengthen the competitive profile of VK2735 within the burgeoning obesity drug market.